News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
255,321 Results
Type
Article (13677)
Company Profile (256)
Press Release (241388)
Section
Business (79058)
Career Advice (146)
Deals (13162)
Drug Delivery (27)
Drug Development (50086)
Employer Resources (31)
FDA (5614)
Job Trends (5100)
News (143397)
Policy (10010)
Tag
Academia (900)
Africa (145)
Alabama (26)
Allergies (29)
Alliances (21370)
Alzheimer's disease (675)
Antibody-drug conjugate (ADC) (30)
Approvals (5587)
Arizona (38)
Artificial intelligence (25)
Asia (16586)
Australia (2768)
Bankruptcy (96)
Best Places to Work (4309)
Biotechnology (213)
C2C Services and Suppliers (10603)
California (989)
Canada (430)
Cancer (191)
Career advice (127)
CAR-T (30)
Cell therapy (79)
China (69)
Clinical research (38804)
Collaboration (67)
Colorado (33)
Connecticut (31)
COVID-19 (969)
Cystic fibrosis (58)
Data (89)
Diabetes (27)
Diagnostics (1147)
Earnings (28340)
Employer resources (29)
Europe (35526)
Events (45462)
Executive appointments (56)
FDA (5693)
Florida (92)
Funding (63)
Gene therapy (65)
GLP-1 (254)
Government (1049)
Healthcare (6491)
Hotbed/Location (184112)
Illinois (60)
Indiana (42)
Infectious disease (977)
Inflammatory bowel disease (75)
IPO (7115)
Job creations (856)
Job search strategy (123)
Kansas (51)
Layoffs (173)
Legal (1368)
Liver cancer (24)
Lung cancer (40)
Maryland (157)
Massachusetts (826)
Medical device (2510)
Medtech (2510)
Mergers & acquisitions (6019)
Metabolic disorders (108)
Michigan (33)
Minnesota (59)
Neuroscience (749)
New Jersey (267)
New York (314)
NextGen Class of 2024 (1973)
Non-profit (836)
North Carolina (305)
Northern California (444)
Obesity (65)
Ohio (56)
Opinion (84)
Parkinson's disease (25)
Patents (27)
Peanut (26)
Pennsylvania (237)
People (24592)
Pharmaceutical (41)
Phase I (13614)
Phase II (18042)
Phase III (11488)
Pipeline (60)
Postmarket research (841)
Preclinical (5744)
Press Release (30)
Rare diseases (89)
Real estate (1403)
Regulatory (7978)
Research institute (926)
South America (206)
Southern California (419)
Startups (1961)
Texas (79)
United States (3908)
Vaccines (115)
Washington State (141)
Weight loss (51)
Date
Last 7 days (235)
Last 30 days (1206)
Last 365 days (21517)
2024 (14047)
2023 (22413)
2022 (26822)
2021 (27806)
2020 (23357)
2019 (16225)
2018 (11738)
2017 (13746)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
255,321 Results for "biosplice therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Biosplice Announces Collaboration with Novo Nordisk in Diabetes
Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering first-in-class therapeutics based on small-molecule inhibition of DYRK/CLK kinases, has entered a collaboration with Novo Nordisk to develop drug candidates for the treatment of diabetes.
June 13, 2024
·
4 min read
Business
Biosplice Therapeutics Announces Department of Defense (DoD) Award to Fund Collaboration with The Roskamp Institute to Advance its Neurology Program
Biosplice Therapeutics, Inc. announced that its collaboration with The Roskamp Institute, aimed at developing novel therapies for TBI using Biosplice’s promising small molecule DYRK inhibitors has been selected for funding by the DoD office of the Congressionally Directed Medical Research Programs.
March 8, 2024
·
3 min read
Drug Development
Biosplice Announces Upcoming Presentation of Successful OA-07 Phase 3 Long-Term Structure and Pain & Function Results for Lorecivivint for Treatment of Knee Osteoarthritis at OARSI Conference, and...
Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering first-in-class therapeutics based on small-molecule inhibition of CLK/DYRK kinases, recently completed two Phase 3 trials, OA-07 long-term structure, pain and function study, and OA-21 short-term pain study.
April 18, 2024
·
3 min read
Drug Development
Biosplice Presents Successful Structure and Pain Results from Completed Phase 3 Long-Term Extension Clinical Trial for Lorecivivint for the Treatment of Knee Osteoarthritis
Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering first-in-class therapeutics based on small-molecule inhibition of CLK/DYRK kinases, yesterday presented results from a long-term extension study, OA-07 for its knee OA drug candidate, lorecivivint.
November 13, 2023
·
4 min read
Biotech Beach
Biosplice Therapeutics Announced New Clinical Data for Cirtuvivint (SM08502) at the European Society for Clinical Oncology Meeting
Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major diseases, announced today the presentation of new clinical data for cirtuvivint (SM08502), its first-in-class small-molecule CLK/DYRK inhibitor.
September 29, 2022
·
3 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
3 min read
·
Voyager Therapeutics, Inc.
Drug Development
Biosplice Announces Interim Data from Phase 3 Long-Term Extension Clinical Trial in Knee Osteoarthritis and the Initiation of a New Phase 3 Trial
Biosplice Therapeutics, Inc. announced potential structure-modifying highlights from an ongoing long-term extension study, OA-07, for its knee OA drug candidate, lorecivivint.
December 15, 2022
·
3 min read
Drug Development
Biosplice Announces Data from Recent Clinical Trials in Knee Osteoarthritis and the Initiation of a New Phase 3 Trial
Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering first-in-class therapeutics based on small-molecule inhibition of CLK/DYRK kinases, announced highlights from three Phase 3 clinical trials, OA-07, OA-10 and OA-11 for its knee OA drug candidate, lorecivivint.
November 11, 2022
·
6 min read
Business
EPIC SCIENCES AND BIOSPLICE THERAPEUTICS ANNOUNCE PARTNERSHIP FOR METASTATIC CANCER TRIALS
Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major diseases, and Epic Sciences, Inc., a leading liquid biopsy diagnostic company, announce they are collaborating to incorporate multi-omic profiling in Biosplice’s clinical oncology programs, including Cirtuvivint (SM08502).
January 27, 2022
·
2 min read
Business
Dave Johnson Joins Biosplice Therapeutics Board of Directors
Biosplice Therapeutics, Inc. announced today the addition of Dave Johnson, most recently Founder and CEO of VelosBio, as an independent director to its board.
June 21, 2021
·
2 min read
1 of 25,533
Next